Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases
Open Access
- 24 August 2012
- journal article
- clinical trial
- Published by Wiley in British Journal of Haematology
- Vol. 159 (2) , 164-171
Abstract
Summary: This international retrospective study of 593 Splenic Marginal Zone Lymphoma (SMZL) patients aimed to identify factors that determine treatment initiation and influence lymphoma‐specific survival (LSS). Logistic regression was used to identify the factors associated with treatment. A Cox regression was used to analyse LSS in a derivation cohort of 366 patients. This produced a prognostic index (PI) and enabled the identification of three risk groups. The resulting stratification was validated in another cohort of 227 patients and compared with the Interguppo Italiano Linfomi (IIL) score in the group of 450 patients for whom all the required data were available using an extension of the net reclassification improvement. Haemoglobin concentration (Hb), extrahilar lymphadenopathy and hepatitis C virus status were associated with the initiation of treatment. Hb, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy were independently associated with LSS. Three risk groups with significantly different five‐year LSS (94%, 78% and 69%, respectively) were identified. This stratification (named HPLL on the basis of determinant factors) had a better discriminative power than the IIL score. This system is useful for stratifying SMZL patients into risk groups and may help in the selection of risk‐tailored treatment approaches.Keywords
This publication has 16 references indexed in Scilit:
- Extensions of net reclassification improvement calculations to measure usefulness of new biomarkersStatistics in Medicine, 2010
- Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma GroupBlood, 2010
- Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity?Blood, 2008
- Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteriaLeukemia, 2007
- Splenic marginal zone lymphoma: a prognostic model for clinical useBlood, 2006
- Dichotomizing continuous predictors in multiple regression: a bad ideaStatistics in Medicine, 2005
- Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysisBlood, 2005
- Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profilesCancer, 2003
- Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patientsBritish Journal of Haematology, 2003
- Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patientsBritish Journal of Haematology, 1996